Evidence map›Paper›PMID 42474148›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Reversing Temozolomide Resistance in Glioblastoma Based on Cuproptosis-Mediated Positive Feedback Loop.

Wenjie Feng, Rui Yang, Chang Weng, Chen Li, Wanrui Shi, Yang Chen, Yang Yang, Yi Liu, Pengfei Ge, Hao Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wenjie FengInstitute of Translational Medicine, The First Hospital of Jilin University, Changchun, P. R. China.
Rui YangState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, P. R. China.
Chang WengState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, P. R. China.
Chen LiDepartment of Neurosurgery, The First Hospital of Jilin University, Changchun, P. R. China.
Wanrui ShiState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, P. R. China.
Yang ChenState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, P. R. China.
Yang YangState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, P. R. China.
Yi LiuInstitute of Translational Medicine, The First Hospital of Jilin University, Changchun, P. R. China.ORCID https://orcid.org/0000-0003-0548-6073
Pengfei GeDepartment of Neurosurgery, The First Hospital of Jilin University, Changchun, P. R. China.
Hao ZhangInstitute of Translational Medicine, The First Hospital of Jilin University, Changchun, P. R. China.ORCID https://orcid.org/0000-0002-2373-1100

Funding

MOSTNational Natural Science Foundation of China 52573296National Natural Science Foundation of China 82173027National Natural Science Foundation of China 82372690Postdoctoral Fellowship Program of CPSF GZC20230949Science and Technology Development Program of Jilin Province SKL202302001
6 · The paper itself

Abstract

Glioblastoma (GBM), one of the most lethal human cancers, faces a major therapeutic challenge due to drug resistance. Temozolomide (TMZ), a standard first-line drug for clinical GBM treatment, benefits only a subset of patients, leaving an urgent need for strategies that can restore its efficacy. Herein, we propose that cuproptosis, a recently identified regulated cell death (RCD), is capable of reversing TMZ resistance in GBM. We design copper-TMZ (Cu-TMZ) prodrugs, assembled via the coordination of Cu

Indexed as

cuproptosisglioblastomapositive feedback loopprodrugtemozolomide resistance

Identifiers

PMID42474148
PMCPMC13383701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.